Leukemia Clinical Trial
Official title:
An Open-label Phase II Study of Lorvotuzumab Mertansine (IMGN901) in CD56 Expressing Hematological Malignancies
The goal of this clinical research study is to learn if lorvotuzumab mertansine can help to control blood cancers that have the CD56 tumor marker. The safety of this drug will also be studied.
Study Treatment:
If you are found to be eligible to take part in this study, you will receive lorvotuzumab by
vein on Days 1 and 8 (+/- 2 days) of each cycle. It may take a few minutes or several hours
to receive the study drug. Your doctor will discuss this with you.
All treatments with IMGN901 must be administered at MD Anderson.
Each cycle is 21 days (+/-6 days). However, they may be longer or shorter depending on if/how
the disease responds to the treatment, how your bone marrow reacts to treatment, and what the
doctor thinks is in your best interest.
Your dose of lorvotuzumab may be raised, lowered, and/or delayed if the doctor thinks it is
in your best interest.
Study Visits:
On Day 1 of each cycle, you will have a physical exam.
One (1) time each week during the first 4 cycles, blood (about 1 tablespoon) will be drawn
for routine tests. After Cycle 4, you will have these blood draws 1 time every 2-4 weeks. If
your doctor thinks it is needed, more blood may need to be drawn. The study doctor or study
staff will discuss this with you if more blood is needed.
During the first cycle, all the laboratory evaluations will be done at MD Anderson. After
Cycle 1, you may be able to have these blood draws performed at a local lab or clinic that is
closer to your home, and the results reported to the research nurse of the study at MD
Anderson. The study doctor or study staff will discuss this option with you. The results of
these blood draws will be sent to the study doctor for review.
On Day 21 of Cycle 1 (+/- 7 days), then every 1-3 cycles after that, you will have a bone
marrow aspiration/biopsy to check the status of the disease. If the doctor thinks it is
needed, these may be done more or less often, depending on your response to the study drug.
You will have blood draws and/or bone marrow aspirations at any time that the doctor thinks
it is needed while you are on study.
If you stay on study for more than 6 months and you are not having side effects, you may have
some of the above tests more or less frequently. For example, you may only have a bone marrow
aspiration 1 time every 6-12 months and blood draws 1 time each cycle. The study doctor will
discuss this with you.
Length of Study:
You may take up to 12 cycles of lorvotuzumab. If the doctor thinks it is in your best
interest, you may be able to continue receiving the study drug beyond Cycle 12. You will no
longer be able to take the study drug if the disease gets worse, if intolerable side effects
occur, or if you are unable to follow study directions.
Your participation on the study will be over after follow-up.
End-of-Study Visit:
If you leave the study before the end of Cycle 12, within 30 days (+/- 7 days) after the last
dose of study drug:
- Blood (about 2-3 tablespoons) will be drawn for routine tests.
- If the doctor thinks it is needed, you will have a bone marrow aspirate/biopsy to check
the status of the disease.
Long Term Follow-Up:
If the disease appears to get better and you are responding well to the study drug, you will
return to MD Anderson every 3-6 months for up to 5 years after your last dose of study drug
for the study staff to check how you are doing.
If you cannot return to MD Anderson for these visits, you may be called by a member of the
study staff. The call should last about 10 minutes.
This is an investigational study. Lorvotuzumab is not FDA approved or commercially available.
It is currently being used for research purposes only. The study doctor can explain how the
drug is designed to work.
Up to 60 participants will take part in this study. All will be enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Active, not recruiting |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |